콘텐츠로 건너뛰기
Merck

P6487

Anti-Purinergic Receptor P2Y1 antibody produced in rabbit

affinity isolated antibody, lyophilized powder

조직 및 계약 가격을 보려면 로그인를 클릭합니다.

크기 선택


제품정보 (DICE 배송 시 비용 별도)

NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
polyclonal
Application:
IHC, WB
Citations:
7
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의

biological source

rabbit

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

lyophilized powder

species reactivity

human, rat

technique(s)

immunohistochemistry: suitable, western blot: suitable

UniProt accession no.

storage temp.

−20°C

target post-translational modification

unmodified

Quality Level

Gene Information

human ... P2RY1(5028)
rat ... P2ry1(25265)

General description

Purinergic Receptor P2Y1 is a member of G protein-coupled receptors. The P2Y1 gene is mapped to human chromosome 3q25.2. It is present in the heart, blood vessels, prostate, testis, ovary, and neural tissue.

Immunogen

synthetic peptide corresponding to residues 242-258 of rat or human P2Y1.

Application

Anti-Purinergic Receptor P2Y1 antibody produced in rabbit has been used in western blotting1:200 and immunohistochemistry at a dilution of 1:50.

Biochem/physiol Actions

Purinergic Receptor P2Y1 acts as a receptor for extracellular ATP and ADP. It is essential for ADP-induced platelet activation, aggregation, and thrombosis. P2Y1  also participates in endothelial cell-based nucleotide-induced relaxation and in calcium mobilization. It serves as a potential target for the generation of new antiplatelet compounds and anti-inflammatory strategies.

Physical form

Lyophilized from phosphate buffered saline, pH 7.4, 1% bovine serum albumin and 0.05% sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

적합한 제품을 찾을 수 없으신가요?  

당사의 제품 선택기 도구.을(를) 시도해 보세요.

hcodes

pcodes

Hazard Classifications

Aquatic Chronic 3

저장 등급

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Milka Koupenova et al.
Frontiers in pharmacology, 9, 37-37 (2018-02-15)
Platelets are small anucleated cells present only in mammals. Platelets mediate intravascular hemostatic balance, prevent interstitial bleeding, and have a major role in thrombosis. Activation of platelet purinergic receptors is instrumental in initiation of hemostasis and formation of the hemostatic
Shara Khan et al.
Diabetologia, 57(12), 2535-2545 (2014-09-12)
There is evidence that ATP acts as an autocrine signal in beta cells but the receptors and pathways involved are incompletely understood. Here we investigate the receptor subtype(s) and mechanism(s) mediating the effects of ATP on human beta cells. We
J Simon et al.
Acta biologica Hungarica, 54(2), 191-201 (2003-10-11)
Since the first identification of P2Y receptor sequences in 1993, it has quickly become apparent that this family of the G-protein coupled receptors is very diverse. Members of this receptor family are activated extra-cellularly by a wide variety of adenosine
Anna Wilkaniec et al.
Purinergic signalling, 13(3), 347-361 (2017-05-19)
Abnormalities of alpha-synuclein (ASN), the main component of protein deposits (Lewy bodies), were observed in Parkinson's disease (PD), dementia with Lewy bodies, Alzheimer's disease, and other neurodegenerative disorders. These alterations include increase in the levels of soluble ASN oligomers in
Agnete Kirkeby et al.
Thrombosis and haemostasis, 99(4), 720-728 (2008-04-09)
The haematopoietic hormone erythropoietin (EPO) has neuroprotective properties and is currently being explored for treatment of stroke and other neurological disorders. Short-term, high-dose treatment with EPO seems to improve neurological function of stroke patients but may be associated with increased

관련 콘텐츠

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.